Mankind Pharma to liquidate BSVL subsidiary and integrate its business

Strategic Transactions View source PDF Explain this filing

MANKIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.0%Reaction day

₹2391.10

prior close

₹2405.00

announcement price

After-mkt

timing

Nifty Midcap 150market-0.1%+0.1% vs market

Pharmaceuticals peers, median of 173sector-0.0%+0.0% vs sector

On the reaction day the stock moved 0.1 pts more than Nifty Midcap 150 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

-0.5

15m

-0.5

30m

-0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.0-0.1+0.1-0.0+0.0

Next day

+0.2-0.1+0.3+0.3-0.1

+1.2+0.0+1.2+0.4+0.8

-1.3-1.2-0.1+0.0-1.3

-0.6-1.8+1.1+0.1-0.8

-1.2-1.3+0.1+0.6-1.8

-3.0-2.0-1.0+1.0-4.0

15d

-3.2-2.7-0.5+0.7-3.8

+1.9-6.2+8.1-0.1+2.0

+4.7-10.7+15.4-4.4+9.1

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mankind Pharma board approved voluntary liquidation of its wholly owned subsidiary Bharat Serums and Vaccines Limited (BSVL). BSVL's business will be consolidated into Mankind Pharma on a going concern basis after required approvals and consents are received. Mankind holds 96 percent of BSVL directly, while Appian Properties, another wholly owned subsidiary, holds 4 percent and will receive cash based on an independent valuation. Mankind's shareholding pattern will not change. The move aims to drive operational efficiency, improve resource use, and cut compliance costs.

Likely market impact

Streamlines group structure by folding BSVL into parent. No change in Mankind shareholding. Subject to regulatory approvals.